Moderna’s market worth has almost tripled this yr to greater than $120 billion. Two of its founders, in addition to an early investor, this month made Forbes journal’s record of the 400 richest individuals within the United States.
As the coronavirus unfold in early 2020, Moderna raced to design its vaccine — which makes use of a brand new expertise generally known as messenger RNA — and to plan a security examine. To manufacture the doses for that trial, the corporate obtained $900,000 from the nonprofit Coalition for Epidemic Preparedness Innovations.
The nonprofit group stated Moderna had agreed to its “equitable access principles.” That meant, in keeping with the coalition, that the vaccine can be “first available to populations when and where they are needed and at prices that are affordable to the populations at risk, especially low- and middle-income countries or to public sector entities that procure on their behalf.”
Moderna agreed in May to supply as much as 34 million vaccine doses this yr, plus as much as 466 million doses in 2022, to Covax, the struggling United Nations-backed program to vaccinate the world’s poor. The firm has not but shipped any of these doses, in keeping with a Covax spokesman, though Covax has distributed tens of hundreds of thousands of Moderna doses donated by the United States.
Mr. Bancel stated that many extra doses would have gone to Covax this yr had the 2 events reached a provide deal in 2020. Aurélia Nguyen, a Covax official, denied that, saying, “It became clear early on that the best we could expect was minimal doses in 2021.”
Late final yr, the Tunisian authorities hoped to order Moderna doses. Dr. Hechmi Louzir, who led Tunisia’s vaccine procurement efforts, didn’t know the way to contact Moderna to start talks and requested the U.S. Embassy in Tunisia for assist, he stated. Officials there contacted Moderna, he stated, however nothing got here of it.
“We were very interested in Moderna,” Dr. Louzir stated. “We tried.”